![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
York Pharma | LSE:YRK | London | Ordinary Share | GB00B00QHC86 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMYRK RNS Number : 4455U York Pharma plc 24 June 2009 York Pharma plc ("York" or the "Company") Update on merger discussions The Board of York today announces that the discussions between the Company and ULURU Inc. ("ULURU") concerning a proposed offer ("the Offer") by ULURU for the Company under the Takeover Code on the proposed terms indicated in the joint announcement on 7 April 2009 have been terminated. On 7 April 2009, York and ULURU also confirmed that Uluru had made available to York a $1 million short term secured line of credit, necessary to allow the Company to continue trading through the period needed to complete any formal offer for the Company under the Takeover Code. ULURU has given notice to the Company for the repayment, within 30 days, of the $1 million line of credit (together with accrued interest) previously advanced to the Company by ULURU. York is now actively pursuing alternative funding facilities in order to repay the line of credit within 30 days and to meet its ongoing working capital requirements. If the Company's fund raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations. The Company will provide a further update as and when appropriate. The Board of York understands that ULURU continues to consider its position with respect to the Company and a further announcement will be made as and when appropriate. For more information please contact: +---------------------------------------+----------------------------+ | York Pharma plc | Tel: +44 (0) 1908 764020 | | Richard Anderson, Chief Executive | | | Officer | | | Ian Miscampbell, Chief Financial | | | Officer | | | | | +---------------------------------------+----------------------------+ | Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 | | Hugh Field / Adam Cowen | | | | | +---------------------------------------+----------------------------+ | Financial Dynamics | Tel: +44 (0) 207 831 3113 | | Ben Brewerton / Emma Thompson | | | | | +---------------------------------------+----------------------------+ Collins Stewart Europe Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as Nominated Advisor and broker to York Pharma plc and will not be responsible to anyone other than York Pharma plc for providing the protections afforded to clients of Collins Stewart Europe Limited nor for providing advice in connection with any other matter referred to herein. This information is provided by RNS The company news service from the London Stock Exchange END MSCSEFFLLSUSEEM
1 Year York Pharma Chart |
1 Month York Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions